UroGen Pharma Ltd. Ordinary Shares (URGN)
PHARMACEUTICAL PREPARATIONS
UroGen Pharma Ltd. Ordinary Shares (URGN) is listed on Nasdaq, where it has traded since May 4, 2017.
- Listed On
- Nasdaq
- Listed Since
- May 4, 2017
- Employees
- 291
- Market Cap
- $2.0B
About UroGen Pharma Ltd. Ordinary Shares
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 183 institutions reported holding URGN, with 42.0 million shares worth $1.5 billion in aggregate. The largest reported holder was Rtw Investments, with 4.5 million shares worth $167.2 million. Of the 5 largest holders listed below, 3 added shares and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Rtw Investments | 4,543,895 | $167M | Unchanged |
| BlackRock | 3,201,461 | $118M | Added 12.51% |
| Morgan Stanley | 2,576,363 | $95M | Added 0.64% |
| Kynam Capital Management | 2,434,207 | $90M | Added 8.31% |
| Jefferies Financial Group | 2,199,652 | $81M | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is URGN?
UroGen Pharma Ltd. Ordinary Shares (URGN) is listed on Nasdaq, where it has traded since May 4, 2017.
Who are the largest institutional holders of URGN?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of URGN were Rtw Investments, BlackRock and Morgan Stanley.
How many institutions own URGN?
183 institutions reported a position in URGN for the quarter ended June 30, 2026, worth $1.5 billion in total.
Did institutions buy or sell URGN last quarter?
Of the 5 largest reported holders, 3 added shares and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for URGN.
Every reported institutional holder, plus insider and congressional trades in URGN, on SentiSense.